首页工具

登录

4-1BB/CD137/TNFRSF9 Protein, Cynomolgus, Rhesus, Recombinant (hFc)

产品编号 TMPY-04719

别名: tumor necrosis factor receptor superfamily, member 9

4-1BB/CD137/TNFRSF9 Protein, Cynomolgus, Rhesus, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 44 kDa and the accession number is XP_005544945.1&NP_001253057.1.

TargetMol的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

TargetMol

4-1BB/CD137/TNFRSF9 Protein, Cynomolgus, Rhesus, Recombinant (hFc)

规格	价格/CNY		货期	数量
100 μg	￥ 2,530		5日内发货

大包装超大折扣，点击咨询

更多批次查询请联系客服

生物活性

技术参数

产品性质

参考文献

生物活性	1.Measured by its binding ability in a functional ELISA. 2. Immobilized cynomolgus / rhesus TNFRSF9-Fc at 10μg/mL (100μL/well) can bind biotinylated human TNFSF9 , the EC50 of biotinylated human TNFSF9 is 20-100ng/mL.
产品描述	4-1BB/CD137/TNFRSF9 Protein, Cynomolgus, Rhesus, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 44 kDa and the accession number is XP_005544945.1&NP_001253057.1.

种属	Cynomolgus,Rhesus
表达系统	HEK293 Cells
标签	C-hFc
蛋白编号	XP_005544945.1&NP_001253057.1
别名	tumor necrosis factor receptor superfamily, member 9
蛋白构建	The cynomolgus / rhesus TNFRSF9 (XP_005544945.1/NP_001253057.1) (Met1-Gln186) was expressed with the Fc region of Human IgG1 at the C-terminus. Cynomolgus and Rhesus TNFRSF9 sequences are identical.
蛋白纯度	≥ 95 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC.
分子量	44 kDa (predicted)

内毒素	< 1.0 EU/μg of the protein as determined by the LAL method.
缓冲液	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
复溶方法	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
存储	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice.
研究背景	CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+and CD8+T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials. Soluble forms of CD137 (sCD137) are generated by differential splicing. sCD137 can bind to CD137 ligand to antagonize the costimulatory activities of the membrane-bound CD137 and reduce T cell proliferation and IL-2 secretion.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy

参考文献

1. Sica G,et al.(1999) Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy. Arch Immunol Ther Exp (Warsz). 47(5): 275-9. 2. Nam KO,et al.(2005) The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets. 5(5): 357-63. 3. Wang Q,et al.(2008) Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J. 49(2): 192-200. 4. Melero I,et al.(2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 29(8): 383-90. 5. Thum E,et al.(2009) CD137, implications in immunity and potential for therapy. Front Biosci. 14: 4173-88.

计算器

复溶计算器

重组蛋白稀释计算器

比活力计算器

Volume (to add to vial)

=

Mass (in vial)

÷

Desired Reconstitution Concentration

bottom

技术支持

您可能有的问题的答案可以在重组蛋白操作手册中找到

Keywords

4-1BB/CD137/TNFRSF9 Protein, Cynomolgus, Rhesus, Recombinant (hFc) tumor necrosis factor receptor superfamily, member 9 recombinant recombinant-proteins proteins protein

我们的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

Copyright © 2015-2024 TargetMol Chemicals Inc. All rights reserved. 沪ICP备20019793号-4

沪公网安备 31010602006700号

沪公网安备 31010602006700号

TargetMol Loading

陶术

生物

TargetMol^®中国区唯一合作伙伴

点击进入陶术生物官网

陶术生物

联系我们

电话：

400-820-0310

邮箱：

service@tsbiochem.com

QQ：

2881945090（终端用户）

2885109491（经销商）

经销：

终端：

地址：

上海市静安区江场三路238号8楼